Abstract
Human leukemia-derived dendritic cells show potential as tools for therapy. Leukemic cells of patients with chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), and chronic myelomonocytic leukemia (CMML) will all undergo substantial differentiation toward dendritic cells (DC) and may be used to drive autologous T cells to acquire anti-leukemic cytotoxicity. This article describes the use of these human leukemia-derived dendritic cells for stimulation of allogeneic donor lymphocytes and presents a clinical trial of autologous CML DC-stimulated lymphocytes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 147-155 |
| Number of pages | 9 |
| Journal | Critical reviews in immunology |
| Volume | 21 |
| Issue number | 1-3 |
| State | Published - 2001 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology